The Middle East is a heterogeneous region with substantial variability in social development, wealth and palliative care development. The region has few democracies, strong but diverse religious affiliations, and many of the region's counties are involved in political upheavals or regional conflicts. While the global consumption of opioids has increased throughout the last 30 years, there has been little increase in opioid consumption in the Middle East. This is the first comprehensive study of opioid availability and accessibility of opioids in the Middle East. Data are reported on the availability and accessibility of opioids for the management of cancer pain in 16 of 24 countries. The data are relevant to 329 million of the region's 403 million people (82%). The survey found that with the exception of Israel, opioid availability continues to be low throughout most of the Middle East. Formulary deficiencies are severe in several countries in particular Afghanistan, Iraq, Lebanon, Libya, Palestine and Tunisia. Even when opioids are on formulary, they are often unavailable, particularly in these same countries. Access is also significantly impaired by widespread over-regulation that is pervasive across the region.
introduction
The Middle East is a heterogeneous region with substantial variability in social development, wealth and palliative care development. The region has few democracies, strong but diverse religious affiliations, and many of the region's counties are involved in political upheavals or regional conflicts. Few countries in the region have palliative care policies and in many parts of the region pain management has been surrounded by myth, irrationality and cultural bias [1] .
Most countries in the Middle East lack government policies concerning cancer control and palliative care. The majority of patients with cancer are diagnosed with advanced-stage disease and, often, the only realistic treatment options are pain relief and palliative care. Registry data from the region indicate that the regional burden of cancer continues to increase largely because of an aging and growing local population coupled with an increasing adoption of cancer-causing behaviors, particularly smoking [2] .
With few exceptions, palliative care services are overall not well developed. However, some progress has been made in some countries including Jordan, and several of the Gulf states (Saudi Arabia, Oman and Qatar) [3] .
Many countries in the Middle East still have low opioid consumption [4, 5] (Figure 1 ). While the global consumption of opioids has increased throughout the last 30 years, there has been little increase in opioid consumption in the Middle East (Figure 2 ), despite increasing economic and health care development in some countries of the region.
Supported by the USA's National Cancer Institute (NCI), the Middle East Cancer Consortium (MECC) has invested substantial efforts in promoting palliative care and palliative care education for health care professionals across the Middle East [6] . The goal of these educational activities is to create a Middle Eastern nucleus of clinical leaders who will facilitate continuing educational activities throughout the region. Indeed, such programs have been undertaken in Israel, Turkey, Jordan, Palestine, Egypt, Cyprus and Oman. This is the first comprehensive study of opioid availability and accessibility of opioids in the Middle East. [8] . Afghanistan is also presented in the Asian report [9] .
formulary availability and cost of opioids for cancer pain
The availability of opioids and their cost to consumers are summarized in Figure 3 and show great variability throughout the region. Israel, Qatar and Saudi Arabia had all seven essential opioid formulations available, while Algeria, Iran, Morocco and Syria had available six of the seven formulations. While six countries (Afghanistan, Iraq, Lebanon, Libya, the OPT and Tunisia) reported no immediate release (IR) morphine and four countries had no sustained release morphine (Afghanistan, Iran, Iraq and Libya), all but two countries (Afghanistan and Iraq) had transdermal (TD) fentanyl available. Oxycodone IR was available in six countries and methadone was available in six countries. Iraq had the most limited formulary with only codeine and injectable morphine available. Libya had codeine, injectable morphine and fentanyl TD available.
In the majority of countries (11 of 16), the cost of these medications was free, or <25% of the drug cost was charged to the patient. The opioid analgesics were always or usually available. The cost of medications was fully borne by patients in Afghanistan, Lebanon, Morocco and Syria. Afghanistan, Iraq, Lebanon, Libya. Palestine had interrupted supplies of controlled release and injectable morphine. With the exception of Israel, oxycodone, methadone and fentanyl, when on formulary, were not regularly available in most countries ( Figure 4 ).
regulatory restrictions to accessibility
Countries used a range of regulatory restrictions to limit accessibility of opioids. With the exception of Israel, most countries had considerable restrictions on the accessibility of opioid analgesics as described below and summarized in Figure 12 .
requirement for permission/registration of a patient to render them eligible to receive an opioid prescription Israel, Morocco and Turkey had no restrictions on the eligibility of a patient to receive prescriptions for opioid analgesics, while Lebanon, Libya and Syria had no restrictions on inpatients ( Figure 5 ). In all other countries, patients required a permit or needed to be registered to receive opioids even in an inpatient setting. Opioids for outpatients were never allowed in Iran and Iraq.
requirement for physicians and other clinicians to receive a special authority/license to prescribe opioids In Afghanistan, Israel and Morocco, all physicians were permitted to prescribe opioids ( Figure 6 ). Special authorization was required in most countries for both surgeons and family doctors. Surgeons could only prescribe in emergencies in Algeria and Libya and not at all in Palestine. Major restrictions were in place for family doctors to prescribe opioids in most countries (Iran, Iraq, Libya, Oman, Palestine, Qatar, Syria and Yemen). Nurses and pharmacists were allowed to prescribe opioids in an emergency only in Afghanistan.
requirement for duplicate prescriptions and special prescription forms Special prescription forms were required, and in most of these countries access to these forms is restricted (Figure 7) . Libya, Morocco and Tunisia charged physicians for these prescription forms. Israel had the least restrictive availability of prescription forms.
prescription limits
Eight countries allow physicians to prescribe an amount of opioid analgesics to a patient for more than 2 weeks (Figure 8) . Afghanistan, Libya, Morocco and Palestine had a limit of 7 days or less; Qatar and Turkey 10 days and Egypt 14 days. Supply in Iran depended on the opioid type.
limitations on dispensing privileges
Afghanistan and Morocco report opioids as being available from any pharmacy and that they were usually available ( Figure 9 ). Most other countries reported that opioids were only available in hospital pharmacies. Six countries reported access to the dispensing pharmacies was limited at least half the time and in Iraq they were almost never accessible.
provision for opioid prescribing in emergency situations
An emergency situation is defined as one when there is an immediate need to relieve strong cancer pain but the physician is not able to physically provide a prescription. Examples include a pain crisis at night, on a public holiday or in a remote region. Only in Afghanistan were pharmacists allowed to prescribe in emergency situations. Few countries allowed for telephone or faxed prescriptions or nurse-generated prescriptions.
pharmacist privilege to correct a technical error on a prescription
In the situation of a patient presenting a prescription that contains a technical error (no address, misspelling, missing value etc.), Afghanistan, Algeria, Iran, Libya, Oman and Saudi 
use of stigmatizing terminology for opioid analgesics in regulations
Eight countries had negative language in drug laws: Afghanistan, Iraq, Israel, Lebanon, Morocco, Palestine, Syria and Turkey (Figure 11 ). Driving was forbidden for patients taking opioid medication in eight countries. Cancer continues to be an increasing problem throughout the world with an increase in cancer incidence in low-and middleincome countries. Many adult patients and children in these Middle East countries present with advanced disease [10, 11] . Opioid consumption has been documented in various formats for Middle East countries [3, [12] [13] [14] . While many countries have shown an increase in consumption since 2000, all countries but Israel have 'inadequate' consumption as defined by the International Narcotics Control Board (INCB) with a defined daily dose for statistical purposes per day per million people (S-DDD) of <200 mg oral morphine equivalents [14] . All surveyed countries in the Middle East, except Israel, have <10% of the anticipated Adequacy of Consumption Measure (ACM) for opioids ( Table 1) .
The approach to improving opioid consumption is guided by the World Health Organization (WHO) policy guidelines, Ensuring Balance in National Policies on Controlled Substances, Guidance for availability and accessibility of controlled medicines [15] . Moreover, the WHO Palliative Care Strategy states that medication availability, education and government policy must all be addressed and implemented if adequate pain relief and palliative care are to be provided.
medication availability
The majority of 16 countries surveyed here had limited access to the essential opioids as outlined by the IAHPC. It is striking that even in countries with very limited opioid formularies, TD fentanyl was usually among those medicines available. It is widely recognized that pharmaceutical companies and importers are reluctant to invest in the registration and promotion of products that do not generate significant profit, such as IR oral morphine or oxycodone. In contrast, where there is scope for profit from the promotion and marketing of proprietary products, such as TD fentanyl, there is greater commercial motivation. It is interesting to note that Jordan (not a respondent in this survey), which is among the countries with a relatively low GDP in the region, initiated their own manufacturing process for IR morphine [16] .
education
Much work needs to be done in educating both patients and clinicians in the region on the role of opioids in cancer pain. In a survey of final year medical students in Saudi Arabia [17] , distrurbingly half of the respondents considered cancer pain as untreatable, 40% considered it a minor problem, and almost 60% consider the risk of substance dependancy syndrome to be high with legitimate opioid prescription. In a survey of 122 research article Annals of Oncology physicians in six university hospitals in Tehran, inadequate education and training in this aspect of care was highlighted as a significant barrier to pain management [18] . This lack of knowledge was higher in non-oncology specialists. Almost 70% of oncologists at the National Center for Cancer and Research in Qatar reported awareness of guidelines for pain relief but only 60% indicated that they applied them in their practice [19] . Among nurses in the same hospital, just over half were aware of the WHO Three-step Ladder on Cancer Pain Relief [20] and the authors called for an increase in formal palliative care education. Many countries have commenced palliative care training in the region [21, 22] .
Patient concerns regarding the use of opioids for the management of cancer pain have been evaluated in Jordan [23] , Morocco [24] and Oman [25] . All of these studies demonstrate high levels of patient reluctance and fears regarding the use of opioids to relieve pain.
government policies and regulations
With the exception of Israel, every responding country in the region reported very high levels of restrictive regulations that impaired access to opioids for pain relief (Figure 12 ). Indeed, there is urgent need for regulatory review and the repeal of unnecessarily burdensome barriers to accessibility.
Efforts to improve the situation have been initiated, especially through the Middle East Cancer Consortium [26] . While there has been progress in some countries for the development of palliative care in the Middle East [3, 27] , overall there has not been any substantial increase in opioid consumption since 2006.
As part of a WHO demonstration project, a model for pain relief and palliative care for the Middle East has been established in Jordan. A major educational and program initiative was undertaken at the King Hussein Cancer Centre (KHCC) in 
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Amman. This program included the development of palliative care services for inpatients, outpatients and patients at home. Regulations governing opioid prescribing have been changed to facilitate effective pain management. The national opioid quota has been increased. Cost-effective, generic, immediate-release morphine tablets are now being produced in Jordan. These initiatives have led to a substantial increase in palliative care service utilization. The achieved changes and the unusually rapid and effective institutionalization of palliative care serve as a model for other countries in the Middle East [16] . Strategies for improvement are given in the 'Next steps in access and availability of opioids for the treatment of cancer pain: reaching the tipping point?', the final chapter of this supplement [28] .
conclusion
With the exception of Israel, opioid availability continues to be low throughout most of the Middle East. Formulary deficiencies are severe in several countries, in particular Afghanistan, Iraq, Lebanon, Libya, Palestine and Tunisia. Even when opioids are on formulary they are often unavailable, particularly in these same countries. Access is also significantly impaired by widespread over-regulation that is pervasive across the region.
There are substantial needs for educational initiatives, as well as formulary and regulatory review and reform in most of the participating countries in this region. 
